National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)s

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

30 Protocols (21 Active Accrual of new subjects, 9 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 18-AR-0081:
Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still s Disease and Related Inflammatory Conditions

* 18-AR-0035:
Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

* 15-AR-0165:
Study of the Natural History, Pathogenesis and Outcome of Melorheostosis - a Rare Osteosclerotic Disease

* 15-AR-0144:
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol

* 15-AR-0060:
The Role of PPAR-Gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

* 14-AR-0200:
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

* 13-AR-0071:
A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms

* 13-AR-0056:
Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis

* 12-AR-8001:
Compassionate Use Treatment Protocol I4V-MC-JAGA; Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK Inhibition

* 12-AR-0159:
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients with Atopic Dermatitis

* 11-AR-0223:
Studies on the Natural History and Pathogenesis of Spondyloarthritis

* 04-AR-0205:
Progression of Spinal Fusion in Ankylosing Spondylitis

* 03-AR-0173:
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still s Disease, Behcet s Disease, Juvenile Dermatomyositis (JDM),and other Undifferentiated Autoinflammatory Diseases)

* 02-AR-0131:
Collection Of Blood Components Using Apheresis from Patients with Rheumatic or Kidney Diseases and Healthy Volunteers

* 01-AR-0227:
Studies of the Natural History of Rheumatic Disease in Minority Communities

* 00-AR-0222:
Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions

* 99-AR-0004:
Molecular Basis of Primary Immunodeficiencies

* 96-AR-0102:
Evaluation and Treatment of Subjects with Dermatologic Diseases

* 96-AR-0097:
The Acquisition of Blood and Skin Samples from Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases

* 94-AR-0066:
Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)

* 91-AR-0196:
Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases

Active Follow-up, Protocols NOT Recruiting New Patients 

* 15-AR-0185:
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies

* 15-AR-0012:
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects with Merkel Cell Carcinoma

* 13-AR-0005:
A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study with an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients with Lupus (STOP LUPUS)

* 08-AR-0148:
A Pilot Study of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease

* 06-AR-0198:
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

* 03-AR-0133:
Clinically Important Changes in Rheumatoid Arthritis

* 03-AR-0131:
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study

* 03-AR-0130:
Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study

* 02-AR-0156:
A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients with Dermatomyositis and Polymyositis

12/15/2018